Estimating the prevalence of generalized and partial lipodystrophy: Findings and challenges

Diabetes, Metabolic Syndrome and Obesity

Volumn 10, Issue , 2017, Pages 375-383

  Chiquette, Elaine ^a   Oral, Elif A ^b   Garg, Abhimanyu ^c   Araújo Vilar, David ^d   Dhankhar, Praveen ^e  

^a Aegerion Pharmaceuticals   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d University of Santiago de Compostela ^*  (Spain)

^e Complete HEOR Solutions ^*  (United States)

Author keywords

Adipose tissue; Atypical diabetes; Dyslipidemia; Hypertriglyceridemia; Insulin resistance; Lipodystrophy; Prevalence

Indexed keywords

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; EUROPEAN; GENERALIZED LIPODYSTROPHY; HUMAN; ICD-9-CM; LIPODYSTROPHY; PARTIAL LIPODYSTROPHY; POPULATION RESEARCH; PREVALENCE; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 85032855200     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s130810     Document Type: Article

References (33)

1. EUROPLAN Partners. Recommendations for the Development of National Plans for Rare Diseases Guidance Document 20100601; 2010. Available from: http://www.europlanproject.eu/Resources/docs/2008-2011_2.EUROPLANRecommendations.pdf. Accessed August 23, 2016.
2. Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe’s Challenges; 2008. Available from: http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf. Accessed August 23, 2016.
3. EUR-Lex. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC 2014. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&qid=1421232837997&from=EN. Accessed August 23, 2016.
4. United States Food and Drug Administration Department of Health and Human Services [webpage on the Internet]. 21CFR316.20 - Content and Format of a Request for Orphan-Drug Designation; 2015. Available from: http://www.ecfr.gov/cgi-bin/text-idx?SID=ad1729044e3018c44badef3eb3824efe&mc=true&node=se21.5.316_120&rgn=div8. Accessed August 23, 2016.
5. European Medicines Agency. Points to Consider on the Calculation and Reporting of the Prevalence of a Condition for Orphan Designation; 2002. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/09/WC500003773.pdf. Accessed August 24, 2016.
6. Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM. 2011;104(11):971-979.
7. Leadley RM, Lang S, Misso K, et al. A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases. Orphanet J Rare Dis. 2014;9:173.
8. Hallal C, Kieling CO, Nunes DL, et al. Diagnosis, misdiagnosis, and associated diseases of achalasia in children and adolescents: a twelveyear single center experience. Pediatr Surg Int. 2012;28(12):1211-1217.
9. Rother KI, Brown RJ. Novel forms of lipodystrophy: why should we care? Diabetes Care. 2013;36(8):2142-2145.
10. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015;307(4):291-298.
11. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157.
12. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500-4511.
13. Garg A. Clinical review: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313-3325.
14. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine. 2004;83(1):18-34.
15. Garg A. Lipodystrophies. Am J Med. 2000;108(2):143-152.
16. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82(2):129-146.
17. Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 1999;84(1):170-174.
18. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19(1):107-116.
19. Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17-26.
20. Savage DB, Semple RK, Clatworthy MR, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94(1):10-16.
21. European Medicines Agency. Public Summary of Opinion on Orphan Designation: Metreleptin for the Treatment of Berardinelli-Seip Syndrome; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/08/WC500131635.pdf. Accessed August 30, 2016.
22. European Medicines Agency. Public Summary of Opinion on Orphan Designation: Metreleptin for the Treatment of Lawrence Syndrome; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/08/WC500131630.pdf. Accessed August 30, 2016.
23. European Medicines Agency. Public Summary of Opinion on Orphan Designation: Metreleptin for the Treatment of Barraquer-Simons Syndrome; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/08/WC500131630.pdf. Accessed August 30, 2016.
24. European Medicines Agency. Public Summary of Opinion on Orphan Designation: Metreleptin for the Treatment of Familial Partial Lipodystrophy; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/08/WC500131629.pdf. Accessed August 30, 2016.
25. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220-1234.
26. van Maldergem L [database on the Internet]. Berardinelli-Seip Congenital Lipodystrophy; 2009. Available from: http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=1007&Disease_Disease_Search_diseaseGroup=congenital-generalizedlipodystrophy&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Berardinelli-Seip-congenital-lipodystrophy&title=Berardinelli-Seip-congenital-lipodystrophy&search=Disease_Search_Simple. Accessed August 30, 2016.
27. Vantyghem M-C [database on the Internet]. Partial Acquired Lipodystrophy; 2006. Available from: http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=11131&Disease_Disease_Search_diseaseGroup=79087&Disease_Disease_Search_diseaseType=ORPHA&Disease(s)/group%20of%20diseases=Partial-acquired-lipodystrophy&title=Partial-acquiredlipodystrophy&search=Disease_Search_Simple. Accessed August 30, 2016.
28. Vantyghem M-C [database on the Internet]. Acquired Generalized Lipodystrophy; 2009. Available from: http://www.orpha.net/consor/cgibin/Disease_Search.php?lng=EN&data_id=11130&Disease_Disease_Search_diseaseGroup=acquired-generalized-lipodystrophy&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Acquired-generalized-lipodystrophy&title=Acquired-generalized-lipodystrophy&search=Disease_Search_Simple. Accessed August 30, 2016.
29. Vigouroux C [database on the Internet]. Familial Partial Lipodystrophy; 2015. Available from: http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=13323&Disease_Disease_Search_diseaseGroup=familial-partial-lipodystrophy&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Familial-partial-lipodystrophy&title=Familial-partiallipodystrophy&search=Disease_Search_Simple. Accessed August 30, 2016.
30. United States Food and Drug Administration Department of Health and Human Services [webpage on the Internet]. FAQ Document 2015; 2015. Available from: https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm240819.htm. Accessed March 1, 2017.
31. Brown LD, Cat TT, DasGupta A. Interval estimation for a proportion. Stat Sci. 2001;16:101-133.
32. Sergeant ESG [webpage on the Internet]. Epitools Epidemiological Calculators; 2017. Available from: http://epitools.ausvet.com.au/content.php?page=CIProportion. Accessed May 4, 2017.
33. Akinci B, Onay H, Demir T, et al. Natural history of congenital generalized lipodystrophy: a nationwide study from Turkey. J Clin Endocrinol Metab. 2016;101(7):2759-2767.